MediPrint™ Ophthalmics Announces It Has Initiated Its SIGHT-2 Phase 2b Clinical Study for Its Lead Asset

Company Also Announces Move into New San Diego Headquarters

SAN DIEGO–(BUSINESS WIRE)–Today, MediPrint™ Ophthalmics, an emerging San Diego-based clinical stage eye care pharmaceutical company focused on enhancing vision for life, announces it has initiated its SIGHT-2 dose-finding Phase 2b study for its proprietary drug-eluting contact lens for glaucoma. This is the second study in its SIGHT (Sustained Innovative Glaucoma and ocular Hypertension Treatment) clinical program aimed at treating mild to moderate glaucoma and ocular hypertension. SIGHT-2 is designed to assess dose optimization for the Company’s lead asset, LL-BMT1, a drug-eluting contact lens to treat glaucoma, and is preceded by the successful completion of the Company’s SIGHT-1 study that validated the MediPrint™ process and contact lenses for treating human subjects.

The concluded SIGHT-1 trial successfully achieved its objectives by showing a favorable safety and tolerability profile and demonstrated a sustained efficacy signal from a single dose. Consequently, MediPrint is proceeding with this previously announced SIGHT-2 study for LL-BMT1, a weekly medicated contact lens releasing bimatoprost to treat open angle glaucoma and ocular hypertension. Patient enrollment is slated to begin imminently.

“I’m excited we’re starting our SIGHT-2 clinical study because this is a key milestone in MediPrint’s plan to provide a necessary ocular treatment option for millions of contact lens wearing patients,” said Praful Doshi, Founder, Chairman, and Interim CEO. “Eye care professionals and glaucoma patients alike are eagerly seeking an alternative to administering ophthalmic drops daily and our weekly medicated contact lens will fulfill that need. We expect to finalize our LL-BMT1 dose by the first half of 2023 as we continue progressing on our path toward FDA submission.”

MediPrint™ has retained CBCC Global Research to facilitate the regulatory, clinical operations, data management and biometric services for the SIGHT-2 study. “CBCC is thankful to the MediPrint™ management and board members for their confidence in both our team and ability to execute,” stated Manoj Vyas, CEO for CBCC Global Research.

The Company also announces a move into its new San Diego headquarters. The larger facility will house corporate offices along with research and development functions and an ISO compliant GMP manufacturing facility. The new building and larger space will facilitate MediPrint™ scaling its current and future pipeline and is equipped to allow for developing both clinical and commercial stage product.

About MediPrint™ Ophthalmics

MediPrint™ Ophthalmics is an emerging San Diego-based clinical stage eye care pharmaceutical company focused on enhancing vision for life by developing and commercializing a proprietary contact lens based ocular drug delivery portfolio. There are over 40 million soft contact lens wearers in the United States alone and most of them will develop some eye disease or condition in their lifetime. Treating their disease or condition with eye drops is inconvenient and frustrating, leading millions to become non-compliant or to be forced to drop out of contact lens wear. The Company’s goal is to offer new treatment options that allow millions of patients to continue wearing their contact lens while the lens correcting their vision also delivers drugs to treat their underlying disease or condition. The Company is currently advancing its lead asset, a unique and complete glaucoma treatment, to the clinic while continuing to build out its product portfolio for dry eye and for allergy, and subsequently for other anterior and posterior segment conditions. Approximately 5% of glaucoma patients in the United States wear contact lenses and MediPrint’s innovative drug-eluting, comfort-enhancing, preservative-free contact lens may be an ideal treatment option for them. MediPrint Ophthalmics’ patented MediPrint process offers a unique value proposition for patients, practitioners, strategic partners, and payers.

For more information, please visit www.mediprintlens.com.

About CBCC Global Research™

CBCC Global Research is a full-service, specialty contract research organization offering a wide variety of clinical research services for the advancement of clinical development programs in Ophthalmology, Oncology, Neurology, Psychiatry and other therapeutic areas. CBCC offers end-to-end services for clinical trials, including clinical operations, site management, safety management, clinical data management & statistical analysis and medical & scientific writing.

For more information, please visit www.cbcc.global.

Contacts

Media Contact:

Orlando Rodrigues

COR Communications

760-212-5727

[email protected]

For CBCC:

Sanjeev Ganatra

CBCC Global Research

714-697-6853

[email protected]